NCT04526184

Brief Summary

Patients with COPD that a pulmonologist classifies between Stage 1-2 in accordance with the GOLD criteria and age and gender-matched healthy individuals will be included in the study. In both groups (n = COPD: 17, Healthy: 17), aerobic exercise (AE) in the target heart rate range of 50% intensity, performed by cycling accompanied by blood flow restriction, will be applied.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 17, 2020

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

August 18, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 25, 2020

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 19, 2024

Completed
27 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2024

Completed
Last Updated

March 20, 2024

Status Verified

March 1, 2024

Enrollment Period

3.6 years

First QC Date

August 18, 2020

Last Update Submit

March 19, 2024

Conditions

Outcome Measures

Primary Outcomes (7)

  • creatine kinase

    rhabdomyolysis marker

    30 minutes

  • C reactive protein, neutrophil

    inflammatory marker

    30 minutes

  • oxygen saturation

    blood oxygen saturation

    30 minutes

  • heart rate

    determination of aerobic exercise dose

    30 minutes

  • systolic and diastolic pressure

    to mean arterial pressure calculation

    up to 18 weeks

  • modified borg scale

    dyspnoea measurement, Minimum 1, maximum 7 points are obtained. 5 indicates the best respiratory condition, 10 the worst respiratory condition.

    up to 18 weeks.

  • oxidative stress markers

    uric acid, lactate dehydrogenase

    up to 18 weeks

Study Arms (2)

healthy group

ACTIVE COMPARATOR

25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.

Procedure: aerobic exercise with blood flow restriction

patient group

ACTIVE COMPARATOR

25 individuals will be selected randomly from 103 patients with COPD from hospital records.

Procedure: aerobic exercise with blood flow restriction

Interventions

Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.

healthy grouppatient group

Eligibility Criteria

Age40 Years - 75 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsBecause COPD is generally more common in males, patients of this gender were included in the study.
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • No drug change for at least 30 days for the COPD group
  • Not participating in a structured activity program for at least six months
  • Have the ability to cooperate

You may not qualify if:

  • Presence of any pathology that limits physical activity performance
  • Presence of severe or unstable heart disease
  • Presence of peripheral artery disease
  • Being in an exacerbation period of the disease
  • Presence of another active disease (rheumatic, oncological, traumatic etc.)
  • Any neurological or orthopedic disease that prevents exercise

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karabük Üniversitesi Araştırma Hastanesi Göğüs Hastalıkları Kliniği

Karabük, 78600, Turkey (Türkiye)

Location

Related Publications (7)

  • Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, Abe T, Nielsen JL, Libardi CA, Laurentino G, Neto GR, Brandner C, Martin-Hernandez J, Loenneke J. Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. Front Physiol. 2019 May 15;10:533. doi: 10.3389/fphys.2019.00533. eCollection 2019.

  • Kacin A, Strazar K. Frequent low-load ischemic resistance exercise to failure enhances muscle oxygen delivery and endurance capacity. Scand J Med Sci Sports. 2011 Dec;21(6):e231-41. doi: 10.1111/j.1600-0838.2010.01260.x. Epub 2011 Mar 8.

  • Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. Sports Med. 2015 Mar;45(3):313-25. doi: 10.1007/s40279-014-0288-1.

  • Nolan CM, Rochester CL. Exercise Training Modalities for People with Chronic Obstructive Pulmonary Disease. COPD. 2019 Dec;16(5-6):378-389. doi: 10.1080/15412555.2019.1637834. Epub 2019 Nov 4.

  • Loenneke JP, Allen KM, Mouser JG, Thiebaud RS, Kim D, Abe T, Bemben MG. Blood flow restriction in the upper and lower limbs is predicted by limb circumference and systolic blood pressure. Eur J Appl Physiol. 2015 Feb;115(2):397-405. doi: 10.1007/s00421-014-3030-7. Epub 2014 Oct 22.

  • Wilson JM, Lowery RP, Joy JM, Loenneke JP, Naimo MA. Practical blood flow restriction training increases acute determinants of hypertrophy without increasing indices of muscle damage. J Strength Cond Res. 2013 Nov;27(11):3068-75. doi: 10.1519/JSC.0b013e31828a1ffa.

  • Berzosa C, Cebrian I, Fuentes-Broto L, Gomez-Trullen E, Piedrafita E, Martinez-Ballarin E, Lopez-Pingarron L, Reiter RJ, Garcia JJ. Acute exercise increases plasma total antioxidant status and antioxidant enzyme activities in untrained men. J Biomed Biotechnol. 2011;2011:540458. doi: 10.1155/2011/540458. Epub 2011 Mar 9.

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Exercise

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
25 COPD patients were referred to the study from the pulmonology clinic of the hospital where the study was conducted by a medical secretary who was blinded to the intervention. In addition, 21 healthy individuals volunteered to participate in the study from the same hospital where the study was previously announced.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Two groups will be formed as healthy and patient groups and the same treatment initiative will be applied.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Student

Study Record Dates

First Submitted

August 18, 2020

First Posted

August 25, 2020

Study Start

August 17, 2020

Primary Completion

March 19, 2024

Study Completion

April 15, 2024

Last Updated

March 20, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations